Twitter Beğeni Hilesi

Welcome to the @BCIS4trial X page. This study is funded by the National Institute of Health Research (NIHR) [HTA (NIHR155123]. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care

Rationale and design of the CHIP-BCIS3 randomized controlled trial: LV unloading in high-risk PCI. Just published in Circ CVINT. ➡️ historical challenges of trials in MCS ➡️innovative design and ideal population to deliver a definitive trial bit.ly/4bV3VHu

Thanks to our amazing network of CHIP-BCIS3 BCIS investigators, trial management group, oversight committees, funders and all the patients who have volunteered, we are firmly on track to complete the trial and answer important questions about LV unloading in high-risk PCI!

Mon 8th April (Atlanta) Matt Ryan 0915 (Rm B213) Does LGE predict segmental recovery in severe LVSD? REVIVED analysis 1015 (theater 3) Quality of Life after PCI in severe LVSD: a #WinRatio analysis REVIVED. @JACCjournals Clinical Trials Unit - Global Health Trials Group Mark Petrie John Spertus

In REVIVED, PCI did not prolong life in patients with ischemic LV dysfunction. But what about symptoms? Our detailed analysis of health status and quality of life out this week in JACC: Heart Failure. jacc.org/doi/10.1016/j.…

67 yr male presenting with heart failure (NYHA II), CMR EF 31%, transmural LGE in lateral/anterolat segments. Angiogram: 3VD (calcified prox LAD, severe LCx/OM1, CTO RCA). Surgical turndown due to airways disease. Complete, partial or no revasc? Poll below 👇 #EuroPCR #JACC

How would you manage this patient? A. Complete anatomical revasc (PCI LAD, LCx and RCA) B. Revasc of all viable segments (PCI LAD, RCA) C. PCI LAD only D. OMT

35% voted for OMT; of those opting for PCI 42% would do complete ANATOMICAL revasc and 35% VIABILITY-guided revasc (a minority LAD only). 📣Find out answers when Margaret McEntegart presents eagerly awaited REVIVED LBT 0830 Wed 15 May #EuroPCR with sim pub in #JACC PCRonline 🫀

Thanks to hours of work by independent angio and viability core labs, a carefully designed analysis plan and our dedicated team, we now have answers to many remaining questions about REVIVED! Join us at #EuroPCR and/or read the paper in #JACC on Wednesday 15th May.

Come and join us this morning at 'Randomised trials: substudies and extended follow up' for the REVIVED completeness of revasc presentation by Margaret McEntegart Theatre Havane from 8.30am 🚨 JACC Journals Divaka Perera

#EuroPCR #JACC LBCT SimPub: Insights from #REVIVED-BCIS2 trial - Completeness of #revascularization, whether anatomical or viability-guided, does not influence outcomes in patients with ischemic #cardiomyopathy. bit.ly/44JRcV0 Saad Ezad Margaret McEntegart Cardiac Research

JACC Journals Saad Ezad Margaret McEntegart Cardiac Research We have to challenge dogma and firmly held views with data. REVIVED surprised us all. Severe disease. Extensive revasc. Struggling to find benefit for patients. More trials underway..James Januzzi Jr MD Harriette Van Spall, MD MPH Divaka Perera Elmir Omerovic Margaret McEntegart Roxanna Mehran

Join us this Friday 30th at the #ESCCongress for the final piece of the REVIVED puzzle! 🧩 ➡️ How ischaemic were the patients enrolled in REVIVED? ➡️ Did ischaemic burden identify patients most likely to benefit from PCI? 12:15pm @ Science Box 4!

ESC guidelines for PCI in severe LV impairment changed from 2a LoE C (should be done in most patients, based on consensus) to 2b LoE B (may be done in selected patients, based on randomised data).#ESCCongress 🙏🏽REVIVED investigators for providing the supporting evidence

Fantastic today that 2 landmark RCTs our centre University Hospitals Dorset NHS Foundation Trust recruited patients for impacted ESC guidelines to direct future care: OCTOBER Trial pushing IC imaging toward 1A REVIVED shifting PCI in ICM down to 2bB Great CI leadership Niels R. Holm & Divaka Perera #researchwin🏆

Ischemia analysis of REVIVED #ESCCongress 💜 approx 20% of LV scarred 30% ischemic on CMR 🏥 very high rates of death or aborted sudden death 📈 amount of ischemia not associated with risk of events 📈 no benefit of PCI whether ischemia extensive or mild/moderate

How do we reconcile STICH and REVIVED? Would CABG offer survival benefit with contemporary medical therapy? ➡️ Answers at late breaking science session #ESCCongress2024 this morning! Results from the first pooled individual patient level analyses from these two RCTs

Fascinating talks using pooled data from REVIVED (R) + STICH (S) ➡️ R patients had higher baseline surgical risk ➡️ No difference in tx effect in either trial by surgical risk ➡️ S-OMT arm had worse outcomes than R-OMT ➡️ R-OMT arm had better outcomes than S-CABG! #ESCCongress